Ra Capital Management, L.P. - Jun 4, 2025 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Signature
/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Stock symbol
ABOS
Transactions as of
Jun 4, 2025
Transactions value $
$0
Form type
4
Date filed
6/5/2025, 06:12 PM
Previous filing
Jun 2, 2025
Next filing
Jun 9, 2025

Reporting Owners (5)

Name Relationship Address Signature Signature date CIK
RA CAPITAL MANAGEMENT, L.P. Director, 10%+ Owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON /s/ Peter Kolchinsky, Manager of RA Capital Management, L.P. 2025-06-05 0001346824
RA Capital Healthcare Fund LP Director, 10%+ Owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON /s/ Peter Kolchinsky, Manager of RA Capital Healthcare Fund GP, LLC, the General Partner of RA Capital Healthcare Fund, L.P. 2025-06-05 0001315082
RA Capital Nexus Fund II, L.P. Director 200 BERKELEY STREET, 18TH FLOOR, BOSTON /s/ Peter Kolchinsky, Manager of RA Capital Nexus Fund II GP, LLC, the General Partner of RA Capital Nexus Fund II, L.P. 2025-06-05 0001825376
Kolchinsky Peter Director, 10%+ Owner C/O RA CAPITAL MANAGEMENT, L.P., 200 BERKELEY STREET, 18TH FLOOR, BOSTON /s/ Peter Kolchinsky, individually 2025-06-05 0001384859
Shah Rajeev M. Director, 10%+ Owner C/O RA CAPITAL MANAGEMENT, L.P., 200 BERKELEY STREET, 18TH FLOOR, BOSTON /s/ Rajeev Shah, individually 2025-06-05 0001619841

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABOS Common Stock Award $0 +12.8K $0.00 12.8K Jun 4, 2025 See footnotes F1, F2, F3
holding ABOS Common Stock 13M Jun 4, 2025 See footnotes F2, F4
holding ABOS Common Stock 1.3M Jun 4, 2025 See footnotes F2, F5
holding ABOS Common Stock 589K Jun 4, 2025 See footnotes F2, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABOS Stock Option (Right to Buy) Award $0 +19.5K $0.00 19.5K Jun 4, 2025 Common Stock 19.5K $1.07 See Footnotes F2, F3, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the grant of a restricted stock unit ("RSU") award to Laura Stoppel pursuant to the Issuer's non-employee director compensation policy. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of June 4, 2026 or the Issuer's 2026 annual stockholder meeting, subject to Dr. Stoppel's continuous service as a director through such vesting date.
F2 RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
F3 Under Dr. Stoppel's arrangement with the Adviser, Dr. Stoppel holds the RSU and the option for the benefit of the Fund and the Nexus Fund II. Dr. Stoppel is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option or settlement of the RSU, as applicable, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the RSU, the option and underlying common stock.
F4 Held directly by the Fund.
F5 Held directly by the Nexus Fund II.
F6 Held directly by the Account.
F7 Represents the grant of an option to Dr. Stoppel pursuant to the Issuer's non-employee director compensation policy. The shares subject to the option will vest on the earlier of June 4, 2026 or the 2026 annual stockholder meeting, subject to Dr. Stoppel's continuous service as a director through such vesting date.

Remarks:

Laura Stoppel, a Principal of the Adviser, serves on the Issuer's board of directors.